Mechanisms and prevention of restenosis: From experimental models to clinical practice

Cardiovascular Research

Volumn 31, Issue 6, 1996, Pages 835-846

  Bauters, Christophe ^a   Meurice, Thibaud ^a   Hamon, Martial ^a   McFadden, Eugène ^a   Lablanche, Jean Marc ^a   Bertrand, Michel E ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Coronary angioplasty; Growth factors; Hyperplasia; Platelets; Restenosis; Smooth muscle cell proliferation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPEPTIN; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CILAZAPRIL; CIPROSTENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GROWTH FACTOR; HEPARIN; KETANSERIN; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; SULFINPYRAZONE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TRAPIDIL;

CELL PROLIFERATION; CORONARY ARTERY DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; INTIMA; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE; THROMBOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CELL DIVISION; CORONARY DISEASE; HUMANS; HYPERPLASIA; MUSCLE, SMOOTH, VASCULAR; RECURRENCE; TUNICA INTIMA;

EID: 0030011766     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00038-7     Document Type: Review

References (181)

1. Gruentzig A, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis. Percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68.
2. deFeyter PJ, Serruys PW. Percutaneous transluminal coronary angioplasty for unstable angina. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia: WB Saunders, 1994:274-291.
3. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
4. Holmes DR Jr, Berger, PB. Complex and multivessel dilation. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia: WB Saunders, 1994:231-250.
5. Vogel RA. Elective supported angioplasty registry: benefit of prophylactic cardiopulmonary bypass support in low ejection fraction. Circulation, 1992;86(Suppl I):I-787-I-780(Abstract).
6. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med 1988;318:1734-1737.
7. Liu MW, Roubin GS, King III SB. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989;79:1374-1387.
8. Bauters C, Lablanche JM, McFadden EP, Leroy F, Bertrand ME. Clinical characteristics and angiographic follow-up of patients undergoing early or late repeat dilation for a first restenosis. J Am Coll Cardiol 1992;20:845-848.
9. Bauters C, McFadden EP, Lablanche JM, Quandalle P, Bertrand ME. Restenosis rate after multiple percutaneous transluminal coronary angioplasty procedures at the same site: a quantitative angiographic study in consecutive patients undergoing a third angioplasty for a second restenosis. Circulation 1993;88:969-974.
10. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Topol, EJ, ed. Textbook of Interventional Cardiology. Philadelphia: WB Saunders, 1994:415-435.
11. Herrman JPR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the holy grail? (Part I). Drugs 1993;46:18-52.
12. Franklin SM, Faxon DP. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery Dis 1993;4:232-242.
13. Schwartz SM, deBlois D, O'Brien ERM. The intima. Soil for atherosclerosis and restenosis. Circ Res 1995;77:445-465.
14. Bauters C, De Groote P, Adamantidis M, et al. Proto-oncogene expression in rabbit aorta after wall injury. First marker of the cellular process leading to restenosis after angioplasty? Eur Heart J 1992;13:556-559.
15. Miano JM, Viasic N, Tota RR, Stemerman MB. Localisation of fos and jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol 1993;142:715-724.
16. Pardee AB. G1 events and regulation of cell proliferation. Science 1989;246:603-608.
17. Reed JC, Alpers JD, Nowell PC, Hoover RG. Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci USA 1986;83:3982-3986.
18. Riabowol KT, Vosatka RJ, Ziff EB, Lamb NJ, Feramisco JR. Microinjection of fos-specific antibodies blocks DNA synthesis in fibroblast cells. Mol Cell Biol 1988;8:1670-1676.
19. Heikkila R, Schwab G, Wickstrom E, et al. A c-myc antisense oligodesoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987;328:445-449.
20. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
21. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994;93:820-828.
22. Thyberg J, Hedin U, Sjölund M, et al. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990;10:966-990.
23. Schwartz SM, Campbell CR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986;58:427-444.
24. Rubbia L, Gabbiani G. Phénotype des cellules musculaires lisses artérielles et athérosclérose. Med/Sciences 1989;53:389-395.
25. Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured-rat carotid artery. Circ Res 1987;61:296-300.
26. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab Invest 1985;52:611-616.
27. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992;86:723-729.
28. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-333.
29. Rubbia L, Gabbiani G. The cytoskeleton of arterial smooth muscle cells during development, atheromatosis and tissue culture. J Cardiovasc Pharmacol 1989;14(Suppl 6):S9-S11.
30. Boyd CD, Kniep AC, Pierce RA, et al. Increased elastin mRNA levels associated with surgically induced intimal injury. Conn Tiss Res 1988;18:65-78.
31. Bauters C, Marotte F, Hamon M, Robert V, Samuel JL, Rappaport L. Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries. Circulation 1995;92:904-911.
32. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-1293.
33. Clowes AW, Clowes MM, Kocher O, Ropraz P, Chaponnier C, Gabbiani G. Arterial smooth muscle cells in vivo: relationship between actin isoform expression and mitogenesis and their modulation by heparin. J Cell Biol 1988;107:1939-1945.
34. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375.
35. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and in the hypercholesterolemic Yucatan micropig. Circulation 1994;89:2816-2821.
36. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89:2809-2815.
37. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Comhill JF, Chisolm GM. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995;76:996-1002.
38. Austin GE, Norman NB, Hollman J, Tabei S, Phillips VF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-375.
39. Johnson DE, Hinohara T, Selmon MR, Braden LJ, Simpson JB. Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study. J Am Coll Cardiol 1990;15:419-425.
40. Isner JM, Kearney M, Bauters C, et al. Use of human tissue specimens obtained in vivo by directional atherectomy to study restenosis and related human vascular disorders. Trends Cardiovasc Med 1994;4:213-221.
41. Ueda M, Becker AE, Tsukada T, Numano F, Fujimoto T. Fibrocellular tissue response after percutaneous transluminal coronary angioplasty. An histochemical analysis of the cellular composition. Circulation 1991;83:1327-1332.
42. Ohara T, Nanto S, Asada S, Komamura K, Wang DY. Ultrastructural study of proliferating and migrating smooth muscle cells at the site of PTCA as an explanation for restenosis. Circulation 1988;78(Suppl II):90(Abstract).
43. O'Brien ER, Alpers CE, Stewart DK, et al. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res 1993;73:223-231.
44. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 1993;91:1469-1480.
45. Mintz GS, Douek PC, Bonner RF, et al. Intravascular ultrasound comparison of de novo and restenotic coronary artery lesions. J Am Coll Cardiol 1993;21:118A-1180(Abstract).
46. Kovach JA, Mintz GS, Kent KM, et al. Serial intravascular ultrasound studies indicates that chronic recoil is an important mechanism of restenosis following transcatheter therapy. J Am Coll Cardiol 1993;21:484A-4840(Abstract).
47. Lindner V, Reidy MA, Fingerle J. Regrowth of arterial endothelium. Denudation with minimal trauma leads to complete endothelial cell regrowth. Lab Invest 1989;61:556-563.
48. Weidinger FF, McLenachan JM, Cybulski MI, et al. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 1990;81:1667-1679.
49. Haudenschild CC, Schwartz SM. Endothelial regeneration. II. Restitution of endothelial continuity. Lab Invest 1979;41:407-418.
50. Reidy MA, Clowes AW, Schwartz SM. Endothelial regeneration. V. Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab Invest 1983;49:569-575.
51. Reidy MA, Standaert D, Schwartz SM. Inhibition of endothelial cell regrowth. Cessation of aortic endothelial cell replication after balloon catheter denudation. Arteriosclerosis 1982;2:216-220.
52. Fishman JA, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening. Lab Invest 1975;32:339-351.
53. Stemerman MB, Spaet TH, Pitlick F, Cintron J, Lejnieks I, Tiell ML. The pattern of reendothelialization and intimal thickening. Am J Pathol 1977;87:125-142.
54. Gravanis MB, Roubin GS. Histopathologic phenomena at the site of percutaneous transluminal coronary angioplasty: the problem of restenosis. Hum Pathol 1989;20:477-485.
55. Hamon M, Vallet B, Bauters C, et al. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994;90:1357-1362.
56. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic-guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
57. Guo J, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ Res 1994;75:77-84.
58. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
59. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
60. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-1058.
61. Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 1993;87(suppl V):V-51-V-55.
62. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986;231:405-407.
63. McNamara DB, Bedi B, Aurora H, et al. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1993;193:291-296.
64. Taguchi J, Abe J, Okasaki H, Takuwa Y, Kurokawa K. L-arginine inhibits neointimal formation following balloon injury. Life Sci 1993;53:387-392.
65. Fingerle J, Johnson R, Clowes AW, et al. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989;86:8412-8416.
66. Goldberb ID, Stemerman MB. Vascular permeation of platelet factor 4 after endothelial injury. Science 1980;209:611-612.
67. Friedman RJ, Stemerman MB, Wenz B, et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. J Clin Invest 1977;60:1191-1201.
68. Willerson JT, Yao SK, McNatt J, et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991;88:10624-10628.
69. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250.
70. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993;91:94-98.
71. Berk BC, Taubman MB, Griendling KK, et al. Thrombin stimulated events in cultured vascular smooth muscle cells. J Biol Chem 1990;265:1734-1740.
72. den Heijer P, Foley DP, Escaned J, et al. Angioscopic versus angiographic detection of intimal dissection and intracoronary thrombus. J Am Coll Cardiol 1994;24:649-654.
73. Bauters C, Lablanche JM, McFadden EP, Hamon M, Bertrand ME. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis. Circulation 1995;92:2473-2479.
74. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and or sudden death. Circulation 1985;71:699-708.
75. De Groote P, Bauters C, McFadden EP, Lablanche JM, Leroy F, Bertrand ME. Local lesion-related factors and restenosis after coronary angioplasty: evidence from a quantitative angiographic study in patients with unstable angina undergoing double-vessel angioplasty. Circulation 1995;91:968-972.
76. Bauters C, Khanoyan P, McFadden EP, Quandalle P, Lablanche JM, Bertrand ME. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis. Circulation 1995;91:1410-1418.
77. Assoian RK, Grotendorst GR, Miller DM, Sporn MB. Cellular transformation by coordinate action of three peptide growth factors from human platelets. Nature 1984;309:804-806.
78. Walker LN, Bowen-Pope DF, Ross R, Reidy MA. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proloferation after arterial injury. Proc Natl Acad Sci USA 1986;83:7311-7315.
79. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 1988;82:1134-1143.
80. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-1132.
81. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106-113.
82. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990;85:2004-2008.
83. Lindner V, Majack RA, Reidy MA. Basic FGF induces the proliferation of vascular cells in injured arteries. FASEB J 1990;4:A625.
84. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-3743.
85. Bassols A, Massaque J. Transforming growth factor b regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Biol Chem 1988;263:3039-3045.
86. Nikol S, Isner JM, Pickering JG, Kearaey M, Leclerc G, Weir L. Expression of transforming growth factor-b1 is increased in human vascular restenosis lesions. J Clin Invest 1992;90:1582-1592.
87. Border WA, Ruosslahti E. Transforming growth factor-b in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
88. Sporn MB, Roberts AB, Wakefield LM, de Combrugghe B. Some recent advances in the chemistry and biology of transforming growth factor-b. J Cell Biol 1987;105:1039-1045.
89. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type b. Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4170.
90. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor-b is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989;86:4544-4548.
91. Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res 1990;66:1755-1760.
92. Dzau VJ. Vascular renin angiotensin: a possible autocrine or paracrine system in control of vascular function. J Cardiovasc Pharmacol 1984;6:S377-S382.
93. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994;93:339-346.
94. Berk BC, Vekhstein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth mucle cells. Hypertension 1989;13:305-314.
95. Turla MB, Thompson MM, Corjay MH, Owens GK. Mechanisms of angiotensin II- and arginine vasopressin-induced increases in protein synthesis and content in cultured rat aortic smooth muscle cells. Circ Res 1991;68:288-299.
96. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
97. Powell JS, Müller RKM, Kuhn H, Hefti F, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
98. Van Belle E, Vallet B, Auffray JL, et al. Chronic inhibition of nitric oxide synthesis reverses the effects of ACE inhibition on neo-endothelium-dependent relaxation and on intimal thickening after balloon injury. Am J Physiol 1996;270:H298-H305.
99. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72:1202-1210.
100. Van Belle E, Bauters C, Wemert N, et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, an aldosterone antagonist. Cardiovasc Res 1995;29:27-32.
101. Vanhoutte PM, Houston D. Platelets, endothelium and vasospasm. Circulation 1985;72:728-734.
102. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 1986;83:674-678.
103. Moalic JM, Bauters C, Himbert D, et al. Phenylephrine, vasopressin and angiotensin II as determinants of proto-oncogene and heat-shock protein gene expression in adult rat heart and aorta. J Hypertension 1989;7:195-201.
104. Iwaki K, Sukhatme VP, Shubeita HE, Chien KR. Alpha- and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. J Biol Chem 1990;265:13809-13817.
105. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
106. Clozel M, Fischli W, Guilly C. Specific binding of endothelin on human vascular smooth muscle cells in culture. J Clin Invest 1989;83:1758-1761.
107. Komuro I, Kurihara H, Sugiyama T, Takaku F, Yasaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988;238:249-259.
108. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Arteriosclerosis 1989;78:225-228.
109. Douglas SA, Louden C, Vickery-Clark LM, et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res 1994;75:190-197.
110. Azuma H, Hamasaki H, Niimi Y, Terada T, Matsubara O. Role of endothelin-1 in neointima formation after endothelial removal in rabbit carotid arteries. Am J Physiol 1994;267:H2259-H2267.
111. Fingerle J, Tina AUYP, Clowes AW, Reidy MA. Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 1990;10:1082-1087.
112. Walker LN, Ramsay MM, Bowyer DE. Endothelial healing following defined injury to rabbit aorta: depth of injury and mode of repair. Arteriosclerosis 1983;47:123-130.
113. Kulik TJ, Rothman A, Glennon ET, Underwood RH. Stretching vascular smooth muscle causes inositol phosphates turnover. Circulation 1989;80(Suppl 11):198(Abstract).
114. Clowes AW, Clowes MM, Reidy MA. Role of acute distension in the induction of smooth muscle proliferation after endothelial denudation. Fed Proc 1987;46:720.
115. Kohler TR, Jawien A. Flow affects development of intimal hyperplasia after arterial injury in rats. Arterioscler Thromb 1992;12:963-971.
116. Kohler TR, Kirkman TR, Kraiss LW, Zierler BK, Clowes AW. Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts. Circ Res 1991;69:1557-1565.
117. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426-1436.
118. Bauters C, Hamon M, Van Belle E, Dupuis B, Lablanche JM, Bertrand ME. Resténose après angioplastie coronaire. Apport des modèles expérimentaux. Arch Mal Cœur 1993;86:47-56.
119. Faxon DP, Sanborn TA, Haudenschild CC, Ryan TJ. Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am J Cardiol 1984;53:72C-76C.
120. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
121. Darius H, Nixdorff U, Zander J, et al. Effects of ciprostene on restenosis rate and platelet activation during therapeutic PTCA. Eur Heart J 1991;12(Suppl):26(Abstract).
122. Serruys PW, Klein W, Rutsch W, et al. PARK: the Post Angioplasty Restenosis Ketanserin Trial. J Am Coll Cardiol 1992;21:322A(Abstract).
123. Serruys PW, Rutsch W, Heyndrickx G, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with tromboxan A2 receptor blockade. Circulation 1991;84:1568-1580.
124. Yabe Y, Okamoto K, Oosawa H, et al. Does a thromboxane A2 synthetase inhibitor prevent restenosis after PTCA? Circulation 1989;80(Suppl 2):II-260(Abstract).
125. Finci L, Meier B, Steffenino G, Rutishauser W. Aspirin versus placebo after coronary angioplasty for prevention of restenosis. Eur Heart J 1988;9(Suppl):156(Abstract).
126. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-886.
127. Pukac LA, Hirsch GM, Lormeau JC, Petitou M, Choay J, Karnovsky MJ. Antiproliferative effects of novel, non anticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo. Am J Pathol 1991;139:1501-1509.
128. Hamon M, Bauters C, Wernert N, et al. Heparin does not inhibit oncogene induction in rabbit aorta following balloon denudation. Cardiovasc Res 1993;27:1209-1213.
129. Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB. Effect of 18-24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-782.
130. Faxon DP, Sprio T, Minor S, et al. Enoxaparin, a low molecular weight heparin, in the prevention of restenosis after angioplasty: results of a double blind randomised trial. J Am Coll Cardiol 1992;19:258A(Abstract).
131. Sarembock IJ, Gertz SD, Gimple LW, et al. Effectiveness of recombinant desulphato hirudin in redacting restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991;84:232-243.
132. Serruys PW, Deckers JW, Close P, on behalf of the HELVETICA study group. A double blind, radomized, heparin controlled-trial evaluating acute and long-term efficacy of r-hirudin (CGP 39 393) in patients undergoing coronary angioplasty. Circulation 1994;90:I-394(Abstract).
133. MERCATOR study group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study: a multicenter, randomised, double-blind placebo-controlled trial. Circulation 1992;86:100-110.
134. MARCATOR study group. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995;2:362-369.
135. Constantinescu DE, Banka VS, Tulenko TN. Lovastatin inhibits proliferation of arterial smooth muscle and endothelial cells. Indication in atherosclerosis and prevention of restenosis. Eur Heart J 1992;13(Suppl):82(Abstract).
136. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-259.
137. Weintraub WS, Bocuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-1337.
138. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1990;318:549-557.
139. Dehmer GJ, Popma JJ, Van Den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988;319:733-740.
140. Milner MR, Gallino RA, Leffingwell A, et al. Usefulness of fish oil supplement in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1989;64:294-299.
141. Grigg LE, Kay TWH, Valentine PA, et al. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. J Am Coll Cardiol 1989;13:665-672.
142. Reis GJ, Boucher TM, Sipperly ME, et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989;2:177-181.
143. Liu MW, Roubin GS, Robinson KA, et al. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 1990;81:1089-1093.
144. Okamoto S, Masaaki I, Setsuda M, Konishi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor (PDGF) antagonist in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1439-1444(Abstract).
145. STARC study group. Trapidil (platelet-derived growth factor inhibitor) prevents restenosis after PTCA: results of the STARC study. Eur Heart J 1993;14(abstr Suppl):277.
146. Lundergan C, Foegh ML, Vargas R, et al. Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034. Arteriosclerosis 1989;80:49-55.
147. Santoian EC, Schneider JE, Gravanis MB, et al. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Circulation 1993;88:11-14.
148. Hierowski MT, Liebow C, DuSpain K, Schally AV. Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett 1985;179:252-256.
149. Bauters C, Van Belle E, Wernert N, et al. Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation. Circulation 1994;89:2327-2331.
150. Emanuellson H, Beatt KJ, Bagger JP, et al. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. Circulation 1995;91:1689-1696.
151. Kent KM, Williams DO, Cassagneau B, et al. Double-blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty. Circulation 1993;88(Suppl I):I-506(Abstract).
152. Whitworth HB, Roubin OS, Hoilman J, et al. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986;8:1271-1276.
153. Corcos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985;109:926-931.
154. Pepine CJ, Hirshfeld JW, McDonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990;81:1753-1761.
155. Grines CL, Rizik D, Levine A, et al. Colchicine angioplasty restenosis trial (CART). Circulation 1991;84:II-365(Abstract).
156. ACCORD Study Group. Nitric oxide donors reduce restenosis after coronary angioplasty. J Am Coll Cardiol 1994;23(Suppl):59A(Abstract).
157. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990;82:2190-2200.
158. Karas SP, Gravanis MB, Robinson KA, Anderberg A, Hearn JA, King SB. Comparison of the response to coronary artery balloon injury and stenting in swine: an animal model of restenosis. Circulation 1990;82(Suppl III):III-497(Abstract).
159. Van Belle E, Bauters C, Wernert N, et al. Angiotensin converting enzyme inhibition prevents proto-oncogene expression in the vascular wall after injury. J Hypertension 1995;13:105-112.
160. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
161. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
162. Wolinski H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 1990;15:475-481.
163. Fram DB, Aretz TA, Mitchel JF, et al. Localized intramural delivery of a marker agent during balloon angioplasty: a new technique using hydrogel-coated balloons and active diffusion. Circulation 1992;86:I-380(Abstract).
164. Camenzind E, Reys A, Ligthart J, et al. Local intracoronary delivery of heparin and of a somatostatin analogue (octreotide) following angioplasty in man: evaluation of efficacy of delivery by radio-isotopic technique. J Am Coll Cardiol 1995;Abstract Supplement: 285 A(Abstract).
165. Hong MK, Bhatti T, Matthews BJ, et al. Locally delivered angiopeptin reduces intimal hyperplasia following balloon injury in rabbits. Circulation 1991;84:II-72(Abstract).
166. Wilenski RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J 1991;122:1136-1141.
167. March KL, Mohanraj S, Ho P, Wilenski RL, Hathaway DR. Biodegradable microspheres containing a colchicine analog inhibit DNA synthesis in vascular smooth muscle cells. Circulation 1992;86:I-381(Abstract).
168. Steg PG, Feldman L, Scoazec JY, et al. Percutaneous delivery of adenovirus for arterial gene transfer of endothelial and smooth muscle cells. Circulation 1994;90:1648-1656.
169. Von der Leyen H, Gibbons GH, Morishita R, et al. In vivo gene transfert of nitric oxide synthase inhibits neointima formation in injured rat carotid arteries. Eur Heart J 1994;15:426(Abstract).
170. Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91:2793-2801.
171. Bertrand ME, Lablanche JM, Leroy F, et al. Percutaneous transluminal coronary rotary ablation with rotablator (European experience). Am J Cardiol 1992;69:470-478.
172. Buchbinder M, Leon M, Warth D, et al. Multi-center registry of percutaneous coronary rotational ablation using the rotablator. J Am Coll Cardiol 1992;19:33A(Abstract).
173. Eigler N, Forrester JS. Nonpharmacologic device prevention of coronary restenosis. In: Topol, EJ, ed. Textbook of Iinterventional Cardiology. Philadelphia: WB Saunders, 1994:400-414.
174. Safian RD, Gelbfish JS, Erny RE, et al. Coronary atherectomy: clinical, angiographic, and histological findings and observations regarding potential mechanisms. Circulation 1990;82:69-75.
175. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease: the CAVEAT Study Group. N Engl J Med 1993;329:221-227.
176. Elliott JM, Berdan LG, Holmes DR, et al. One-year follow-up in the coronary angioplasty versus excisional atherectomy trial (CAVEAT I). Circulation 1995;91:2158-2166.
177. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706.
178. Serruys PW, Strauss BH, Beatt KJ, et al. Quantitative follow-up after placement of a self-expanding coronary stem. N Engl J Med 1991;324:13-17.
179. Mintz GS, Popma JJ, Pichard AD, et al. Differing mechanisms of late arterial responses to transcatheter therapy: a serial quantitative angiographic and intravascular ultrasound study. Eur Heart J 1995;Abstract Supplement:385(Abstract).
180. De Scheerder I, Wilczek K, Van Dorpe J, et al. Angiopeptin loaded stents inhibit the neointimal reaction induced by polymer coated stents implanted in porcine coronary arteries. Circulation 1994;90:I-597(Abstract).
181. Bauters C, Lablanche JM, Renaud N, McFadden EP, Hamon M, Bertrand ME. Morphologic changes after percutaneous transluminal coronary angioplasty of unstable plaques. Insights from serial angioscopic follow-up. Eur Heart J in press.